Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review).

doi:10.3892/IJMM.1.2.491

Paper

Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review).

Published Feb 1, 1998 · I. Müller, D. Niethammer, G. Bruchelt

International journal of molecular medicine

Q1 SJR score

203

Citations

3

Influential Citations

Full textSemantic Scholar

Abstract

Anthracycline-derivatives are frequently used chemotherapeutics in treatment of numerous human malignancies. Anthracyclines are known for their complex cytotoxic mechanism involving i) inhibition of enzymes such as topoisomerase II, RNA polymerase, cytochrome c oxidase and others; ii) intercalation into DNA; iii) chelation of iron and generation of reactive oxygen species (ROS); iv) induction of apoptosis. Here, mechanistic aspects for successful cytostasis and for side effects, e.g. cardiomyopathy, are discussed. We emphasize recent developments in anthracycline-mediated apoptosis and focus on a well known representative, doxorubicin (adriamycin, adriblastin). We reflect on the role of oxidative stress and interactions with intracellular signaling pathways.

Highly Cited

Study Snapshot

Anthracycline-derived chemotherapeutics effectively kill cancer cells by inducing apoptosis and oxidative stress, with potential side effects like cardiomyopathy.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review).

Sign up to use Study Snapshot

References

Citations

Modelling post-chemotherapy stem cell dynamics in the bone marrow niche of AML patients

The 7+3 regimen in acute myeloid leukemia patients requires a 10-fold increase in hematopoietic stem-like cell proliferation rates to recapitulate the cell dynamics observed in complete remission, suggesting G-CSF priming may improve treatment outcomes.

Phytohemagglutinin from Phaseolus vulgaris enhances the lung cancer cell chemotherapy sensitivity by changing cell membrane permeability.

Phytohemagglutinin from Phaseolus vulgaris enhances lung cancer cell chemotherapy sensitivity by changing cell membrane permeability, offering a novel strategy to combat drug resistance in lung cancer treatment.

Chemical-induced phase transition and global conformational reorganization of chromatin

Adriamycin, a widely used anticancer drug, induces local condensation and global conformational change in chromatin in cancer and primary cells, affecting chromatin interaction and transcriptomic changes.

Four Genes Predictive for the Severity of Hematological Damage Reveal a Similar Response after X Irradiation and Chemotherapy

The gene set identified for predicting hematological acute radiation syndrome (H-ARS) after irradiation is similarly deregulated after chemotherapy, potentially aiding in early diagnosis and treatment of hematological acute radiation syndrome.

Label-Free and Bioluminescence-Based Nano-Biosensor for ATP Detection

Gold nanoparticles improve the stability and accessibility of ATP in bioluminescence-based ATP biosensors, enabling low-cost, easy-to-use cell viability measurements.

Antioxidant, anti-inflammatory, and anti-apoptotic effects of crocin against doxorubicin-induced myocardial toxicity in rats

Crocin may be a cardioprotective agent in cancer patients treated with doxorubicin, improving lipid profile, cardiac markers, and oxidative stress indices.

PROTECTIVE EFFECT OF NANOCURCUMIN AGAINST NEUROTOXICITY INDUCED BY DOXORUBICIN IN RAT'S BRAIN.

Nanocurcumin protects against some of the neurotoxic effects of doxorubicin in rats, making it more tolerable for cancer patients.

Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor

Inhibiting BPTF with small-molecule inhibitors can enhance the effectiveness of TOP2-targeted cancer chemotherapeutic drugs in triple-negative breast cancer models.

Bioreductive Activation of Antitumour Drugs, Doxorubicin and Pirarubicin, Does Not Affect Their Ability to Induce Apoptosis of Sensitive and Multidrug Resistant Leukaemia HL60 Cells

Bioreductive activation of doxorubicin and pirarubicin does not affect their ability to induce apoptosis of sensitive and resistant HL60 leukaemia cells.